Neurol. praxi. 2022;23(2):146-154 | DOI: 10.36290/neu.2021.045

Fingolimod treatment of multiple sclerosis at any age

doc. MUDr. Radomír Taláb, CSc.1, MUDr. Marika Talábová2
1 MS Centrum Teplice, Neurologická klinika LF UK a FN Plzeň
2 MS Centrum Hradec Králové, Neurologická klinika LF UK a FN Hradec Králové

Fingolimod was approved in Europe until the 2nd line of treatment for relapsing multiple sclerosis in children and adult patients. It is also recommended in the first line for a highly active form of multiple sclerosis. The results of phase 2, phase 3 (TRANSFORMS, FREEDOMS) and phase 3b (LONGTERMS) clinical trials are presented, which evaluate longitudinal efficacy, safety and MR data of fingolimod in real clinical practice. The fundamental benefit of long-term collection of clinical data from real clinical practice is highlighted, which complemented data on the efficacy and safety of fingolimod and the reduction of the most common adverse reactions of randomized multicentre studies - lymphopenie, liver enzyme elevation, basal cellular carcinoma. The results of the PARADIGMS clinical study demonstrated the efficacy and safety of fingolimod for the pediatric MS population from the age of 10 years.

Keywords: multiple sclerosis, fingolimod, LONGTERMS, PARADIGMS, pediatric MS.

Received: June 17, 2021; Revised: June 17, 2021; Accepted: June 17, 2021; Prepublished online: June 17, 2021; Published: April 21, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Taláb R, Talábová M. Fingolimod treatment of multiple sclerosis at any age. Neurol. praxi. 2022;23(2):146-154. doi: 10.36290/neu.2021.045.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Chitnis T, Arnold DL, Banwell B, et al. PARADIGMS Study Group. Trial of Fingolimod versus Interferon Beta-1a in Pedia­tric Multiple Sclerosis. N Engl J Med. 2018;379(11):1017-1027. Go to original source... Go to PubMed...
    2. Cohen JA, Barkhof F, Comi G, et al. TRANSFORMS Study Group. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362:402-415. Go to original source... Go to PubMed...
    3. Cohen M, Maillart E, Tourbah A, et al. Switching form natalizumab fo fingolimod in multiple sclerosis. A French prospective study. JAMA Neurology. 2014, JAMA neurol.doi:10.1001/jamaneurol.2013.6240. Go to original source... Go to PubMed...
    4. Cohen JA, Tenebaum N, Bhatt A, et al. Extended treatment with fingolimod for relapsing multiple sclerosis: The 14-year LONGTERMS study results. Ther Adv Neurol Disord. 2019;12:1-16. Go to original source... Go to PubMed...
    5. Giovannoni G, Naismith RT. Natalizumab to fingolimod washout in patients at risk of PML. Neurology. 2014;82:1-2. Go to original source... Go to PubMed...
    6. Hatcher S, Waubant E, Noubaksh B, et al. Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment Article in JAMA Neurology. 2016:E1-E5. Go to original source... Go to PubMed...
    7. Henault D, Galleguillos L, Moore C, et al. Basis for fluctuations in lymphocyte counts in finmgolimod-treated patients with multiple sclerosis. Neurology. 2013;81:1768-1772. Go to original source... Go to PubMed...
    8. Jokubaitis VG, Li V, Kalincik T, et al. MSBase Study group. Fingolimod after natalizumab and the risk of short-term relapse. Neurology. 2014;82:1-8. Go to original source... Go to PubMed...
    9. Kappos L, Antel J, Comi G, et al. FTY720 D2201 Study Group. Oral fingolimod (FTY720) forrelapsing multiple sclerosis. N Engl J Med. 2006;355:1124-1140. Go to original source... Go to PubMed...
    10. Kappos L, Radue EW, O'Connor P, et al. FREEDOMS Study Group. A placebo controlled trial of oral fingolimod in relapsig multiple sclerosis. N Engl J Med. 2010;362:387-401. Go to original source... Go to PubMed...
    11. Mehling M, Brinkmann V, Antel J, et al. FTY720therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology. 2008;71:1261-1267. Go to original source... Go to PubMed...
    12. Mehling M, Johson TA, Antel J, et al. Clinical Immunology of the sphigosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis. Neurology. 2011;76:S20-S27. Go to original source... Go to PubMed...
    13. Mehling M, Kappos L, Derfuss T. Fingolimod for Multi­ple Sclerosis: Mechanism of Action, ClinicaL Outcomes, and Future Directions. Curr Neuro Neurosci Rep. 2011;11:492-497. Go to original source... Go to PubMed...
    14. Schmidt S, Schulten T. Severe rebound after cessation of fingolimod treated with ocrelizumab with coincidental transient aggravation: report of two cases. Ther Adv Neurol Disord. 2019;12:1756286419846818. Go to original source... Go to PubMed...
    15. Thomas K, Ziemssen T. Management of fingolimod in clinical practice. Clinical neurology and Neurosurgery. 2013;115S:S60-S64. Go to original source... Go to PubMed...
    16. Trina AJ, Shames I, Keezer M, et al. Reconstituion of circulating lymfocyte counts in FTA720-treated MS pacients. Clinical Immunology. 2010;137:15-20. Go to original source... Go to PubMed...
    17. www.sukl.cz gilenya-epar-product-information_cs.pdf SPC Gilenya, 16. 11. 2020.
    18. Ziemssen T, Lang M, Tackengerg B, et al. PANGAEA studijní skupina. Real-world persistence and benefit-risk profile of fingolimod over 36 months in Germany. Neurol Neuro­immunol Neuroinflamm. 2019;6:e548. Go to original source... Go to PubMed...
    19. Ziemssen T, Medin J, Couto AM, Mitchell CR. Multiple scle­rosis in real world: A systematic review of fingolimod as a case study. Autoimunity Reviews. 2017;16:355-376. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.